Cognitive Disorders
Conditions
Brief summary
This is a First-in-Human, Randomized, Placebo-controlled, Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects including Receptor Occupancy Measurements after Single Dose of SDI-118 and an Assessment of Food Effect.
Interventions
DRUGSDI-118
SDI-118 Powder in Capsule
DRUGPlacebo
Matching Placebo
Sponsors
Syndesi Therapeutics
KU Leuven
AbbVie
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male subjects, 18 to 50 years of age, inclusive. * Non-smokers or abstinence from tobacco for at least 3 months prior to screening. * Body mass index (BMI) between 18 and 30 kg/m2, inclusive, with a minimum weight of 50 kg and maximum of 100 kg. * Venous access sufficient to allow blood sampling as per the protocol. * Agree to abstain from alcohol intake 24h before each administration of study drug, during the in-patient period of the study and 24 hours prior to all other out-patient clinic visits. * Have given written informed consent approved by the relevant Ethics Committee (EC) governing the site. * In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the clinical study protocol restrictions and requirements. * Subjects and their partners of childbearing potential must be willing to use 2 methods of contraception, one of which must be a barrier method, for the duration of the study and up to 90 days after the last dose. Specifically, Part B/PET related inclusion criteria: * Adequate arterial circulation in both hands (Allen's test). * MRI scan without clinically significant abnormalities. Specifically, Part C/FE related inclusion criteria: * Subjects are not vegetarian and willing to eat a standardized high fat breakfast including butter and bacon.
Exclusion criteria
* History or symptoms of any significant disease including (but not limited to), neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal (GI), hepatic, or renal disorder. * Positive Hepatitis B surface antigen (HBs Ag), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening. * Use of any medications (prescription or over-the-counter (OTC)), vitamin, mineral, herbal, and dietary supplements (including grapefruit products) within 7 days of study drug administration, or less than 5 half-lives (whichever is longer). * Have an estimated Glomerular Filtration Rate (eGFR) \<80 mL/min/1.73m2. Any of the following findings in the resting ECG: * QTcF\> 450 or \< 300 msec at screening or baseline visit, * Notable resting bradycardia (HR \< 40 bpm) or tachycardia (HR \> 100 bpm) at screening or baseline visit, * Personal or family history of congenital long QT syndrome or sudden death, * Screening or baseline ECG with QRS and/or T wave judged to be unfavourable for a consistently accurate QT measurement (e.g. neuromuscular artefact that cannot be readily eliminated, arrhythmias, indistinct QRS onset, low amplitude T wave, merged T- and U-waves, prominent U waves), * Evidence of atrial fibrillation, atrial flutter, Left Bundle Branch Block (LBBB), Wolf-Parkinson-White Syndrome, or cardiac pacemaker at screening or baseline visit (note: a first degree heart block with PR not exceeding 250 msec can be allowed). Specifically, Part B/PET related
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Adverse Events (AEs) | 21 Days | Adverse events (AEs) will be coded using medical dictionary for regulatory activities (MedDRA). An AE is any untoward medical occurrence in a participant administered a study drug and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical product whether or not considered related to the medical product. An AE is considered serious if, in the view of either the investigator or sponsor, the event: results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires hospitalization or prolongation to hospitalization, or other medically important event. |
| Number of participants with laboratory value abnormalities and/or adverse events (AEs) | 21 Days | Number of participants with potentially clinically significant laboratory values (hematology/chemistry/urinalysis) |
| Number of participants with vital sign abnormalities and/or adverse events (AEs) | 21 Days | Number of participants with potentially clinically significant vital sign values |
| Number of participants with temperature abnormalities and/or adverse events (AEs) | 21 Days | Number of participants with potentially clinically significant temperature values |
| Number of participants with routine 12 lead electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs) | 21 Days | Number of participants with potentially clinically significant ECG values. |
| Number of participants with routine physical examination abnormalities and/or Adverse Events (AEs) | 21 Days | Number of participants with potentially clinically significant changes in physical examination. |
| Number of participants with routine neurological examination abnormalities and/or Adverse Events (AEs) | 21 Days | Number of participants with potentially clinically significant changes in neurological examination. |
| Number of participants with abnormalities on Profile of Mood States (Brief) and/or Adverse Events (AEs) | 21 Days | Number of participants with potentially clinically significant changes in Profile of Mood States (Brief) values. |
| Number of participants with abnormalities on Bond-Lader-VAS and/or Adverse Events (AEs) | 21 Days | Number of participants with potentially clinically significant changes in Bond-Lader VAS values. |
Countries
Belgium
Outcome results
None listed